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Lactic acid bacteria (LAB) represent a heterogeneous group of microorganisms that are naturally present in many foods and
possess a wide range of therapeutic properties. The aim of this paper is to present an overview of the current expanding knowledge
of one of the mechanisms by which LAB and other probiotic microorganisms participate in the prevention and treatment of
gastrointestinal inﬂammatory disease through their immune-modulating properties. A special emphasis will be placed on the
critical role of the anti-inﬂammatory cytokine IL-10, and a brief overview of the uses of genetically engineered LAB that produce
this important immune response mediator will also be discussed. Thus, this paper will demonstrate the critical role that IL-10
plays in gastrointestinal inﬂammatory diseases and how probiotics could be used in their treatment.
1. LacticAcid Bacteria
Lactic acid bacteria (LAB) constitute a phylogenetically
heterogeneous group of ubiquitous microorganisms that
are naturally present in media rich organic products, such
as foods and occupy a wide range of ecological niches
ranging from the surface of plants to the gastrourogenital
tract of animals. Currently, the LAB group includes a
large number of cocci and bacilli, such as species of the
genera Carnobacterium, Enterococcus, Lactobacillus, Lacto-
coccus, Leuconostoc, Oenococcus, Pediococcus, Streptococcus,
Tetragenococcus, Vagococcus and Weissella, all presenting a
G+C content in their DNA lower than 55%. Although
quite diverse, the members of this group have various
characteristics in common, that include being (i) gram-
positive, (ii) facultative anaerobes, (iii) nonsporulating, (iv)
nonmotile, and (v) possess the capacity to convert sugars
into lactic acid [1, 2] .T h eﬁ r s tg e n o m eo fL A B( Lactococcus
lactis ssp. lactis IL1403) was sequenced and published in
2001. To date, 31 complete LAB genomes have already been
sequenced, annotated, and published, while 67 projects are
currently ongoing [3].
LAB are one of the most important industrial groups
of bacteria, being widely used in food production, health
improvement, and production of macromolecules, enzymes,
and metabolites [4]. Since the 1980’s, many eﬀorts have
been made to better understand the molecular basis of LAB’s
technological properties in order to control the industrial
processes involving these important microorganisms.
LAB have been used since ancient times in food fer-
mentation processes and preservation. Due to their lack of
pathogenicity, most LAB species, excluding some pathogenic
microorganisms such as Streptococcus pneumonia,a r ec o n -
sidered to be “GRAS” (generally recognized as safe) by2 ISRN Gastroenterology
the US Food and Drug Administration. In addition to
their important technological properties in food production
(production of lactic acid, decrease of lactose, improvement
of organoleptic, and physical characteristics), various species
of LAB, such as Lactobacillus casei, Lactobacillus delbrueckii,
Lactobacillus acidophilus, Lactobacillus plantarum, Lacto-
bacillus fermentum, and Lactobacillus reuteri,h a v eb e e n
shown to possess therapeutic properties since they are able
to prevent the development of some diseases as shown
mostly using animal models [5], they have the capacity to
promote beneﬁcial eﬀects in human and animal health and
[6], are therefore, referred to as being “probiotic.” This term
was popularized by R. Fuller in 1989 and was deﬁned as
“living microorganisms which upon ingestion in adequate
quantities confer a beneﬁt to the host’s health” [7]. Probiotic
organisms can exert their eﬀects locally or during transient
passagethroughthegastrointestinalsystem[6],andthemost
common means of administration is still their inclusion in
fermented dairy products.
Some of the health beneﬁts which have been claimed
for probiotics include improvement of the normal micro-
biota, prevention of infectious diseases and food allergies,
reduction of serum cholesterol, anticarcinogenic activity,
stabilization of the gut mucosal barrier, immune adjuvant
properties, alleviation of intestinal bowel disease symptoms,
and improvement of the digestion of lactose in intolerant
hosts [8]. The most commonly used strains as probiotics
are members of lactobacilli, enterococci, and biﬁdobacteria
groups [6].
Although some of these therapeutic applications have
been questioned, growing concerns about health and well-
being, along with an interest in consuming natural foods,
have drawn considerable attention to probiotics, especially
in the dairy products industry. Currently, many milk
products containing probiotics are available on the market
[9]. The speciﬁc health eﬀects of selected probiotic strains
are becoming increasingly accepted and relief of lactose
intolerance symptoms, shortening of rotavirus diarrhea, and
treatment of allergies are now well established. However,
many proposed beneﬁcial eﬀects of probiotics still need fur-
therresearch,andmoreinformationabouttheirmechanisms
of action are needed before they can be considered for the
prevention and treatment of speciﬁc diseases [6].
Besides their use as probiotics, LAB have potential use
for new applications, such as the production of heterologous
molecules of medical and biotechnological interest, such
as cytokines, enzymes, and antigens in bioreactors, in
fermented food products or directly in the digestive tract
of humans and other animals [1]. The most promising new
application for LAB is their use as live delivery vectors for
antigenicortherapeuticproteindeliverytomucosalsurfaces.
Such engineered LAB are able to elicit both mucosal and
systemic immune responses. Eﬃcient expression systems
have already been developed for controlled and targeted
production of desired antigens to be presented to the
gastrointestinal mucosal immune system [10–12]. Currently,
the majority of vehicles used for vaccine delivery are derived
from pathogenic microorganisms; nevertheless, and despite
using attenuated strains, the risk associated with possible
reversion of these pathogens to a virulent phenotype is
am a j o rc o n c e r n[ 13]. The use of LAB as DNA delivery
vehicles represents an attractive alternative to the use of such
attenuated pathogens.
2.Interleukin-10
Interleukin-10(IL-10)isapluripotentcytokineandthemost
important anti-inﬂammatory cytokine found within the
human immune response [14]. IL-10 was ﬁrst described as a
productofT-helpertype2(Th2)cellsthatinhibitedcytokine
synthesis in Th1 cells, and receiving as such the designation
of cytokine synthesis inhibition factor (CSIF) [15–17]. IL-
10 is now known to be produced by numerous immune cell
populations such as macrophages, monocytes, dendritic cells
(DC), B cells, as well as Th2, Th1, CD4+CD25+ naturally
occurring regulatory T cells (nTreg), Tr1 and CD8+ cells [18,
19] and as such, modulates the function of several adaptive
immunity-related cells. IL-10 can induce development of IL-
10-producing T cells by acting on antigen-presenting cells
(APCs) such as dendritic cells and/or directly on the Treg
cells. Tolerogenic DC can inﬂuence the development and
activity of regulatory T cells [18]. Furthermore, receptors
for IL-10, IL-10R1, and IL-10R2, are expressed on many
cell types and can also be observed in IL-10-producing
cells, suggesting that the IL-10-secreting cells can themselves
also be targets [18]. However, IL-10 is also produced by
nonimmune cell sources such as keratinocytes, epithelial
cells, and even tumor cells [18, 20].
Human IL-10 is a homodimer with a molecular mass of
37kDa and each monomer consists of 160 amino acids. The
human IL-10 gene is located on chromosome 1 and encodes
for ﬁve exons [21]. Human and murine IL-10 sequences
exhibit a 80% homology approximately [14].
IL-10 exerts a profound eﬀect on immune responses
having the ability to diﬀerently aﬀect the function of several
immune cell subsets and is, therefore, considered to be a
broad eﬀector molecule in immunoregulation/host defense
[14]. IL-10 is generally considered an immunosuppressive
molecule with its main biological function being the limiting
and termination of inﬂammatory responses and the regula-
tion of diﬀerentiation and proliferation of several immune
cells such as T cells, B cells, natural killer cells, APCs, mast
cells, and granulocytes [14]. However, IL-10 also mediates
immunostimulatory properties in several in vitro and in vivo
models [21]. The balance between both immunostimulatory
and immunosuppressive eﬀects is greatly inﬂuenced by
the dominant cell function determining a given immune
phenomenon. Thus, IL-10 can directly regulate innate and
adaptive Th1 and Th2 responses by limiting T cell activation
and diﬀerentiation in the lymph nodes as well as suppressing
proinﬂammatory responses in tissues, leading to impaired
pathogen control and/or reduced immunopathology [22].
As such, all the activities of IL-10 aﬀects the inﬂamma-
tory or speciﬁc cellular immune response (Th1, cytokine
proinﬂammatory secretion by macrophages, and modula-
tion of Th2) and stimulates functions of innate immunity
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cells, and microbes by stimulating phagocytosis) and of
Th2 related immunity. Thus, it inhibits the production of
proinﬂammatory mediators while enhancing the production
of anti-inﬂammatory mediators [14].
IL-10 has an eﬀect on survival, proliferation, and
diﬀerentiation of human B cells as well as inducing IgA
and IgG production by B cells. Regarding the eﬀects on
T cells, IL-10 inhibits the production of IL-2 and IFN-
γ by Th1 cells [23, 24] and decreasing T cell-mediated
immunity while enhancing humoral immune response. IL-
10 also promotes antigen uptake by DC [25, 26], inhibits
DC migration [27, 28], and increases the expression of toll-
like receptors (TLR) on monocyte lineage cells [29, 30].
Moreover, IL-10 also stimulates NK cell cytotoxicity [21,
31]. The eﬀects of IL-10 on immune cells suggest that
the major physiological importance of IL-10 seems to be
the limitation of inﬂammation, prevention of uncontrolled
unregulated immunological reactions as well as the support
of the humoral (Th2) immune response [24]. The powerful
immunomodulatory properties of IL-10 and the promising
results from IL-10 delivery on the course of several inﬂam-
matory diseases in experimental models induced the interest
on clinical application of IL-10. However, inadequate IL-10
expression seems to have a considerable pathological impact.
Both overexpression (e.g., in lymphoma) as well as IL-10
deﬁciency (e.g., in inﬂammatory bowel disease) are likely to
haveaphysiologicalsigniﬁcance.Therefore,neutralizationof
the cytokine could be a promising approach to treat diseases
from the ﬁrst group whereas application of IL-10 itself could
be helpful for diseases from the second group [14]. It is
believed that the reliable manipulation of immune responses
by controlling IL-10 expression in the cellular location where
it is produced may someday become reality [32]. In this
context, the aim of this review is to present an overview of
the current expanding knowledge of one of the mechanisms
by which LAB and other probiotic microorganisms partic-
ipate in the prevention and treatment of gastrointestinal
inﬂammatory disease through their immune-modulating
properties with special emphasis on the critical role of the
anti-inﬂammatory cytokine IL-10.
3. Immunomodulatory Properties of Probiotics
The intestinal mucosa is the body’s ﬁrst line of defense
against pathogenic and toxic invasions from food. After
ingestion, orally administered antigens encounter the GALT
(gut associated lymphoid tissue), which is a well-organized
immune network that protects the host from pathogens
and prevents ingested proteins from hyperstimulating the
immuneresponsethroughamechanismcalledoraltolerance
[33].
The main mechanism of protection given by the GALT
is humoral immune response mediated by secretory IgA
(s-IgA) which prevents the entry of potentially harmful
antigens, while also interacting with mucosal pathogens
without potentiating damage. The stimulation of this
immune response could thus be used to prevent certain
infectious diseases that enter the host through the oral route.
An increasing number of probiotic strains have shown to
highly increase s-IgA, therefore the stimulation of IgA-
producing cells is often considered a must in probiotic
screening trials [34].
The use of pathological models, such as inﬂammatory
bowel disease (IBD) animal models have proven useful in the
elucidation of the immune mechanisms involved in patho-
genesis. For example, it has been shown that a deregulation
of T cells, caused by an imbalance between Treg and Th1,
Th2, and Th17 can cause an excessive production of eﬀector
T cells that can in turn participate in the development and
exacerbation of IBD [35, 36]. Murine models of IBD have
demonstrated that CD4+ T cell diﬀerentiation plays a pivotal
role in determining the type of immune response generated
in the gut and that distinct cytokine proﬁles characterize
each CD4+ T cell subset (Th1, Th2, Th17, and Tr) [37–39].
In Crohn’s disease (CD) patients, an abnormal amount of
CD4+ lymphocytes with Th1 phenotype are present whereas
in patients with ulcerative colitis (UC) there is an imbalance
towards the Th2 phenotype [40]. New immunological
insights implicate Th17 cells in the pathogenesis of CD
and the importance of Th1 and Th17 cells as targets to
treat this pathology [41]. These activated cytotoxic T cells
exacerbate the inﬂammatory process through the release of
proinﬂammatory cytokines and chemokines upon lysis of
epithelial cells and the increased inﬂux of luminal antigens
at the site of epithelial erosions [42].
The tolerogenic eﬀect of the gut microbiota may partially
be mediated by the generation of regulatory T cells (Treg)
or through the stimulation of Th2 cell populations which
promote oral tolerance induction, preventing hypersen-
sitivity and local inﬂammation [43, 44]. It was shown
that L. rhamnosus GG reduced the number of activated T
lymphocytes in the lamina propria of CD mucosa, impeding
the release of IL-6 and TNF-α and lowering the expression of
the antiapoptotic protein Bcl-2 [45].
Numerous studies have shown that certain strains of
lactobacilli and biﬁdobacteria can modulate the production
of cytokines (mediators produced by immune cells) that are
involved in the regulation, activation, growth, and diﬀeren-
tiation of immune cells. These probiotic microorganisms are
able to prevent and treatcertain inﬂammatory diseases in the
gastrointestinal tract through the repression of proinﬂam-
matory cytokines. One of the central transcription factors
mediating inﬂammatory responses is the nuclear factor κB
(NF-κB). NF-κB is required for the transcriptional activation
o fan u m b e ro fi n ﬂ a m m a t o rye ﬀectors, including IL-8, TNF-
α, IL-6, Cox2, iNOS, and many others, and its deregulation
has been detected in many inﬂammatory conditions. It was
shown that a number of LAB can suppress inﬂammatory
signals mediated by NF-κB. These include strains of the
phylogenetically closely related species L. acidophilus and
L. johnsonii, which have been isolated from the human GI
tract and form part of the acidophilus complex. Recent
studies revealed that dairy L. delbrueckii strains that also
belong to the acidophilus complex and that are used in
yoghurtandcheesemakingalsoinhibitNF-κBactivationina
strain-dependent manner in human intestinal epithelial cells
in vitro [C. Santos Rocha et al., in preparation].4 ISRN Gastroenterology
These results are in agreement with the observation
that the administration of probiotic yoghurt, containing
live L. delbrueckii and Streptococcus thermophilus,c a nm o d -
ulate the immune response, inducing downregulation of
inﬂammatory cytokines (IL-17 and IL-12) produced by the
immunecellsinvolved intheinﬂammatoryprocess[46].The
association of toll-like receptor (TLR) signaling deregulation
and the pathogenesis of IBD infer the therapeutic potential
of modulating TLR signaling pathways. Considering that
probiotic bacteria and probiotic fermented products exert
their eﬀects mainly through stimulation of the innate
immune response [8, 47, 48], changes in TLR expression can
be associated to the beneﬁcial eﬀect of these microorganisms
in hosts with IBD [49, 50]. Tolerance of the intestinal
epithelium against bacterial ligands of the intestinal lumen
is mediated by TLRs, which belong to a family of pattern-
recognizing receptors that detect conserved molecular prod-
ucts of microorganisms emerging as crucial elements in the
activation of innate immunity as well as connectors between
the innate and acquired immunity. TLR4 recognizes the LPS
present in the membrane of Gram (−)b a c t e r i as u c ha s
the Enterobacteriaceae family which tends to overgrow in an
inﬂammatoryprocess.InthecolonicmucosaofIBDpatients,
high concentrations of Enterobacteriaceae and bacteroides
were associated with severe inﬂammation and TLR4 increase
[51].Severalstudieshaveshownthatinﬂammatorycytokines
such as IFN-γ and TNF-α increase the expression of TLR4
and MD-2 (myeloid diﬀerentiation protein 2), resulting in
increased LPS responsiveness [52]. In this context, it was
shown that probiotic bacteria such as L. casei CRL 431
can induce changes in the TLR expression in immune and
intestinal epithelial cells [53]. L. casei DN-114 001 prevented
the development of acute DSS-induced colitis in TLR4 KO
mice by inhibiting myeloperoxidase activity and IL-12p40,
andincreasingTGF-βandIL-10mRNA.Theseeﬀectssuggest
that the mechanism of action of L. casei DN-114 001
depends on other factors besides TLR4 status [54].
Although, by deﬁnition, probiotics should be admin-
istered as live microorganisms, isolated components of
probiotic cells may also have therapeutic beneﬁts. It was
reported that bacterial DNA has a potent immunostimu-
latory eﬀect since it could attenuate colitis in a number
of induced and spontaneous murine models [55]. TLR9
recognizes unmethylated CpG sequences in DNA molecules.
The importance of this receptor in the etiology of IBD
was observed in TLR9-deﬁcient mice, where the intestinal
inﬂammation was signiﬁcantly lower and proinﬂamma-
tory cytokine production was drastically reduced [56]. In
this sense, bacterial DNA derived from luminal bacteria
contributes signiﬁcantly to the perpetuation of chronic
intestinal inﬂammation through TLR9. Intestinal epithelial
cells recognize pathogenic bacterial DNA and respond by
increasing surface localization and expression of TLR9,
leading to the secretion of the proinﬂammatory cytokine IL-
8[ 57]. Furthermore, the presence of TLR9 is also associated
with the beneﬁcial eﬀect exerted by probiotics against IBD.
It was reported that the inhibition of experimental colitis by
probiotics was not observed in mice deﬁcient in MyD88 or
TLR9 [58].
In addition, it was also shown that the attenuation of
DSS colitis could be caused by DNA of the VSL#3 probiotic
mixture through TLR9 signaling, and nonviable bacteria
wereequallyeﬀectiveinreducinginﬂammationinthismodel
[59]. Heating E. coli strain Nissle 1917 and its isolated
DNA were also administered in a DSS murine colitis model
and an anti-inﬂammatory eﬀect was demonstrated [60].
Interestingly, speciﬁc immunostimulatory DNA sequences
have also been shown to attenuate the production of
proinﬂammatorycytokineswhichareelevatedinthemucosa
ofUCpatients,suggestingthattheanimalmodeldatamaybe
applicable to human disease states [61].
4. Interleukin-10Modulation by Probiotics
There is no doubt that IL-10 plays a central role in
downregulating inﬂammatory cascades by suppressing the
secretion of proinﬂammatory cytokines. The crucial role of
IL-10 in the prevention of IBD has been demonstrated by
experiments in IL-10-deﬁcient mice. These animals develop
a chronic bowel disease resembling CD in humans, which
is in part caused by a loss of suppression of the mucosal
immune response toward the normal intestinal microbiota
[62]. Unfortunately, systemic IL-10 treatment of CD patients
is not very eﬀective in inducing clinical remission and is
associated with considerable side eﬀects, which are partly
due to the fact that high doses of systemic IL-10 induce the
proinﬂammatory cytokine IFN-γ [63]. However, studies in
experimental models suggest that topical treatment with IL-
10 is eﬀective in preventing certain inﬂammatory diseases.
Recent studies have reported an accumulation of Foxp3+
CD4+ CD25+ cells in colon samples from patients with UC
or CD and that subsets of IL-10-producing CD4+ CD25+
T cells were present mainly within the intestinal lamina
propria, suggesting that chronic intestinal inﬂammation is
not simply a consequence of the absence of Foxp3+ CD4+
Treg cells at the inﬂammation site [64]. One of the ways
by which probiotics can exert immunomodulatory activities
is by increasing IL-10 production that can in turn help in
preventing certain IBD that are caused by abnormal inﬂam-
matory responses. However, not all probiotic strains act in
the same manner. Anti-inﬂammatory eﬀects, such as stimu-
lation of IL-10-producing cells, are strain-dependent traits,
and their eﬀectiveness also depends on the concentrations
used and the method of administration. Some examples of
probiotic strains and mixtures or fermented foods that exert
anti-inﬂammatory eﬀects through the regulation of IL-10
expression are given in Table 1.
Most people think of probiotics as microorganisms that
mustbeconsumedinafoodmatrix;thisisduetothefactthat
the oral administration of probiotics is the most common
method of ingesting these beneﬁcial microorganisms. Oral
administration of a probiotic mixture that consisted of
Biﬁdobacterium longum Bar 33 and L. acidophilus Bar
13 prevented inﬂammation and mucosal ulcerations in
a trinitrobenzene sulfonic acid- (TNBS-) induced colitis
mouse model [82]. This protection was associated with
an upregulation of IL-10 that caused an inhibition of theISRN Gastroenterology 5
Table 1: Examples of probiotic strains/mixtures/fermented foods that exert anti-inﬂammatory eﬀects through the modulation of IL-10.
Demonstrated eﬀect/mechanism Host Ref.
Probiotic mixtures
BIFICO mixture
Prevention of ﬂare-ups of chronic ulcerative colitis/inhibition of
NF-κB activation, decrease the expressions of TNF-α and IL-1β and
increased expression of IL-10
Patients with UC [65]
VSL#3 mixture
Prevention of autoimmune diabetes/increased production of IL-10
from Peyer’s patches and the spleen, increased IL-10 expression in the
pancreas
Nonobese diabetic mice [66]
Antiallergic eﬀect/cytokine production by spleen cells was modulated
towards a Treg/Th0 proﬁle, increased IL-10 and IFN-γ production,
reduction of serum speciﬁc IgG1, reduction of IL-13 and IL-4 mRNA
expression, and increased IL-10 expression at lung level
Allergen-induced mice [67]
Improvement of colitis/increased production of IL-10 and number of
regulatory CD4+ T cells bearing surface TGF-βai nt h ef o r mo f
latency-associated protein
TNBS-induced mice [68]
L. paracasei DSM
13434, L. plantarum
DSM 15312 & 15313
Decreased autoimmune encephalomyelitis/attenuation of
proinﬂammatory Th1 and Th17 cytokines followed by IL-10
induction in mesenteric lymph nodes, and involvement of IL-10
producing CD4(+)CD25(+) Treg cells
Multiple sclerosis mice [69]
Fermented products
Probiotic yogurt
Inhibition of colon tumour growth/decrease of the inﬂammatory
response by increasing IL-10-secreting cells, cellular apoptosis, and
diminishing procarcinogenic enzymes
DMH-induce mice [70]
Reduction of the severity of intestinal inﬂammation/increased levels
of IL-10 in the intestines and decrease in IL-17 and IL-12 levels in
addition to beneﬁcial changes in the intestinal microbiota
TNBS-induced mice [46]
Fermented Maesil
(Prunus mume) with
probiotics
Suppression of the development of atopic dermatitis-like skin
lesions/increased serum concentration of IL-10 and decreased IL-4,
decreases in eosinophil ratio and serum IgE concentration
NC/Nga mouse model [71]
Probiotic strains
L. casei DG Improvement of gut microbiota/reduction of TLR4 and IL-1β mRNA
levels and signiﬁcantly increased mucosal IL-10
Patients with UC [72]
L. casei CRL 431
Increased resistance against Streptococcus pneumonia/improved
production of TNF-α and activity of phagocytes in the respiratory
tract, IL-4 and IL-10 were signiﬁcantly increased, increase in the
levels of speciﬁc respiratory IgA
Malnourished mice [73]
L. rhamnosus GG
Amelioration of intestinal inﬂammation/decreased LPS-induced
cytokine-induced neutrophil chemoattractant-1 production in liver
and plasma, meliorated LPS-suppressed IL-10 level in lungs and
decreased IL-1b production in liver
Gastrostomy-fed rats [74]
L. casei BL23 Protection against colitis/increased IL-10/IL-12 cytokine ratio TNBS-induced mice [75]
L. delbrueckii
UFV-H2b20
Protection against L. monocytogenes/induced higher production of
IL-10 in the mucosal immune system, favored and eﬀector responses
(increased production of TNF-α in the serum, peritoneal cavity, and
gut) while preventing their immunopathological consequences
Germ-free mice [76]
L. salivarius
CECT5713
Improvement of gut microbiota/signiﬁcant increase of NK cells and
monocytes, as well as the plasmatic levels of IgM, A, and G, and the
regulatory cytokine IL-10
Healthy adults [77]
S. cerevisiae UFMG
905
Prevention of bacterial translocation and improvement of intestinal
barrier integrity/increase of IL-10 levels
Murine intestinal obstruction model [78]
L. casei DN-114 001 Prevention of induced colitis/increase in TGF-β and IL-10 mRNA
and protein expression
DSS-induced mice [54]6 ISRN Gastroenterology
Table 1: Continued.
Demonstrated eﬀect/mechanism Host Ref.
GM-strains
L. plantarum
NCIMB8826ΔDlt
Immunomodulatory properties/reduction of secretion of
proinﬂammatory cytokines (TNF-α,I L - 1 β, IL-6, and IL-8), and
increase in IL-10 production
TNBS-induced mice [79]
L. lactis IL-10
Prevention of pulmonary inﬂammation and mucus hypersecretion.
Decrease in eosinophil numbers, EPO activity, anti-OVA IgE, and
IgG1 levels, IL-4, IL-5, CCL2, CCL3, CCL5, and CCL11
OVA-induced mice [80]
Reduction in colitis and histological damages of the
intestines/increased IL-10 levels in the intestines
DSS-induced mice [81]
TNBS-induced increase of the CD4+ population, down-
regulation of IL-12, and a diﬀerent pattern of Foxp3+
CD4+ CD25+ cells in the intraepithelial and lamina propria
lymphocytes [83]. In a human clinical trial, UC patients
that were given the probiotic mixture BIFICO showed a
lower recurrence level of UC ﬂare-ups [65]. This orally
administered probiotic mixture inhibited NF-κB activation,
decreased the expression of TNF-α and IL-1β, and increased
the expression of IL-10.
Continuing in this train of thought, it is logical to
assume that fermented foods containing probiotic micro-
organisms could also be eﬀective in inducing an immun-
ostimulating/anti-inﬂammatory eﬀect. It was shown that
ay o g h u r tp r o d u c e dw i t hap o o lo fp o t e n t i a l l yp r o b i o t i c
LAB strains was eﬀective in inhibiting the propagation
of a dimethylhydrazine- (DMH-) induced colon cancer in
mice by increasing the number of IL-10-secreting cells,
increasing cellular apoptosis and decreasing procarcinogenic
enzymes [70]. Probiotics can also be added to nondairy-
based foods. For example, fermented Maesil (Prunus mume)
containing probiotics was able to suppress the development
of atopic dermatitis-like skin lesions, and caused an increase
in serum concentration of IL-10 and decrease of serum IL-4,
eosinophil ratio, and IgE [71].
Other forms of probiotic administration have also been
shown to be eﬀective in stimulating IL-10 production. A
recent study demonstrated that the rectal administration
of L. casei DG could modify the intestinal microbiota
composition and TLR expression, and increase IL-10 levels
in the colonic mucosa of patients with mild UC [72].
Intranasal administration is also a popular form of probiotic
administration, especially when their eﬀects in lung tissue
or against airborne pathogens are to be evaluated. The
intranasal administration of the VSL#3 probiotic mixture
was shown to signiﬁcantly reduce IL-13 and IL-4 mRNA
expression and increase IL-10 expression in lung tissues,
modulating the development of a Th2-biased response
[67]. An enhanced immune response to pneumococcal
infection was observed in malnourished mice nasally treated
with L. casei CRL 431 as demonstrated by an improved
production of TNF-α, IL-4, IL-10 and IgA in the respiratory
tract [73].
5.IL-10-ProducingLAB
LAB are potential candidates to be used as vehicles for the
productionanddeliveryofheterologousproteinsofvaccinal,
medical, or technological interest and various delivery
systemsarenowavailablefortheseprobioticmicroorganisms
[9].DiﬀerentgeneticengineeringstrategiesinLABhavebeen
used to improve their carbohydrate-fermenting properties
(lactose, galactose), increase speciﬁc metabolite production
(diaceyl, acetoin), produce or increase enzymatic activities
(proteolytic enzymes, α-a n dβ-galactosidase, α-amylase),
or conferring them the capacity to produce beneﬁcial
compounds such as bacteriocins, exopolysaccharide (EPS),
and other sugars, vitamins, antioxidant enzymes, and anti-
inﬂammatory cytokines [84].
Genetically modiﬁed Lactococcus (Lc.) lactis secreting IL-
10 provides a novel therapeutic approach for IBD. The ﬁrst
description of Lc. lactis that can secrete biologically active IL-
10 was published over ten years ago [85]. In this pioneer
study, murine IL-10 was synthesized as a fusion protein,
consisting of the mature part of the eukaryotic protein fused
to the secretion signal of the lactococcal Usp45 protein.
Intragastric administration of this recombinant Lc. lactis
strain prevented the onset of colitis in IL-10 KO mice and
causeda50%reductionoftheinﬂammationinDSS-induced
chronic colitis [81].
The application of IL-10 producing LAB is not only
limited to the treatment of IBD. It was recently shown that
treatment of asthma with a Lc. lactis expressing murine
IL-10 was eﬃcient since this LAB modulated experimental
airway inﬂammation in the mouse model [80]. Lc. lactis
producing recombinant IL-10 used in this study was eﬃcient
in suppressing lung inﬂammation, independently of Treg
cells, since this cytokine plays a central role in the reg-
ulation of inﬂammatory cascades, allergen-induced airway
inﬂammation, and nonspeciﬁc airway responsiveness [86].
In another study, it was shown that oral administration
of an IL-10-secreting Lc. lactis strain could prevent food-
induced IgE sensitization in a mouse model of food allergy
[87]. These studies conﬁrm that IL-10-secreting LAB hold
potential for the treatment of many inﬂammatory diseases
where this cytokine acts as a modulating compound.ISRN Gastroenterology 7
Although a clear positive eﬀect of these recombinant
strains has been demonstrated, the exact mechanism by
which the beneﬁcial eﬀect of the IL-10-producing Lc. lactis
on the mucosa is produced remains unclear. A recent study
has demonstrated the uptake of IL-10-secreting Lc. lactis by
the paracellular route in inﬂamed mucosal tissue in mouse
models of chronic colitis, suggesting that IL-10 production
by these LAB residing inside the mucosa in the vicinity of
responsive cells can improve the local action of IL-10 in
inﬂamed tissue and the eﬃciency of the treatment [88]. In
another study, it was shown that genetically engineered Lc.
lactis secreting murine IL-10 could modulate the functions
of bone marrow-derived DC in the presence of LPS [89].
This data suggest that the beneﬁcial eﬀects of IL-10 secreting
LAB during chronic colitis might involve inhibition of CD4+
Th17 cells and a reduced accumulation of these cells as well
as other immune cells at the site of inﬂammation.
6.ProbioticsandGenetically
ModiﬁedMicroorganisms
Although there is no scientiﬁc evidence that supports the
notion that genetically modiﬁed (GM) foods or microorgan-
isms are dangerous for human consumption, it is necessary
to demonstrate that these are innocuous in order to alleviate
the fears held by the general public associated with the use of
genetically modiﬁed organisms, if we want to use designed
probiotics to extend the range of applications covered by
natural probiotics. Also, the proper design of GM-LAB is
essential in order to eliminate the risks of dissipation in the
environment and prevent the transfer of certain genes (such
as antibiotic resistance genes) to other microorganisms.
The construction of a biological containment system for
a genetically modiﬁed Lc. lactis for intestinal delivery of
human IL-10 is an important step forward for the safe use of
GM-LABforhumantherapeuticpurposes[90].Inthisstudy,
thethymidylatesynthasegeneofLc.lactiswasreplacedbythe
human IL-10 gene, making this strain incapable of growing
when deprived of thymidine or thymine. This strain does
not contain any antibiotic resistance markers and because
of its thymidine auxotrophy, it cannot disseminate in the
environment, making it one of the safest GM strains ever
engineered. This containment system was recently evaluated
in CD patients, and it was shown that no adverse eﬀects
where produced after consuming this GM-LAB and that it
could only be recovered in feces when thymidine was added
[91]. Although only preliminary results from this phase 1
trial were obtained, the use of genetically modiﬁed bacteria
for mucosal delivery of proteins is a feasible strategy in
human with chronic intestinal inﬂammation [91].
Intragastric administration of Lc. lactis genetically mod-
iﬁed to secrete IL-10 in situ in the intestine was shown
to be eﬀective in healing and preventing chronic colitis
in mice. However, its use in humans is hindered by the
sensitivity of Lc. lactis to freeze-drying and its poor survival
in the gastrointestinal tract, reasons for which novel means
for more eﬀective mucosal delivery of therapeutic LAB are
currently being developed [92–94].
7. Conclusions
The results of animal and some human studies demonstrate
that some probiotic strains can successfully modify the
mucosal immune response to modulate the levels of speciﬁc
activation molecules such as cytokines. By increasing IL-10
levelsandinconsequencedecreasinginﬂammatorycytokines
suchasTNF-αandIFN-γ,someLABcanpreventtheappear-
ance of local inﬂammatory diseases and could be used as
an adjunct therapy with conventional treatments. However,
proper multicenter randomized human clinical trials are
necessary to demonstrate the eﬀectiveness of probiotics in
the treatment of IBD and other inﬂammatory diseases.
Although probiotic eﬀects are a strain-dependent trait,
using modern genetic engineering techniques, it is theo-
retically possible to obtain strains that can exert a variety
of beneﬁcial properties. For example, the introduction of
antioxidant enzyme genes in current probiotic strains that
have natural anti-inﬂammatory properties, such as the
ability to modulate the immune-dependant inﬂammatory
processes, could generate very useful strains that could
be applied in the treatment of a variety of inﬂammatory
diseases [95, 96]. These strains could also be included in
treatment protocols since it has been shown that probiotics
can enhance the eﬀectiveness of traditional IBD treatments.
However, before proposing the genetic modiﬁcation of
anti-inﬂammatory strains, the innate mechanisms of the
potential host strains should be demonstrated in properly
designed large-scale human clinical trials. These trials are
essential in future studies using the engineered strains to
demonstrate the diﬀerences between the native and modiﬁed
strains.
The consumption of engineered strains by humans is still
highly controversial due to the public perception that genetic
manipulation is not “natural.” Scientists must perform well-
designed studies where the results are divulged to the general
population in order to inform consumers of the obvious
beneﬁcial eﬀects these novel techniques can confer with the
minimumofrisktotheirhealthandtotheenvironment[97].
Throughout the course of history, most novel treatments
have met resistance from potential benefactors, it is thus
important to show that the potential beneﬁts are highly
superior to the risks for novel treatments to be completely
accepted by the population as a whole.
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